A multicenter study is investigating a “wearing off” phenomenon in some patients with acetylcholine receptor antibody positive generalized myasthenia (AChR gMG) receiving ravulizumab maintenance infusions. Despite initial efficacy in the CHAMPION MG phase III study, where scheduled dosing every 8 weeks achieved sustained symptom control, instances of symptom fluctuation between treatment cycles have been noted in clinical practice. Among 46 patients treated with ravulizumab, 16 (35%) report experiencing this wearing off before their next infusion, prompting further investigation into patient-specific factors contributing to this phenomenon, with detailed longitudinal data set to be analyzed. The study aims to extract and analyze patient demographics, symptom characteristics, and treatment-specific data to understand factors linked to the observed drift in efficacy. By presenting early clinical experiences with ravulizumab and identifying potential patient-specific factors contributing to the wearing off phenomenon, the research seeks to enhance understanding of ravulizumab’s effectiveness in AChR gMG treatment.

Reference: Ho D, Clifford K, Blum S, et al. Treatment fluctuations in patients with acetylcholine receptor antibody positive generalized myasthenia gravis on maintenance ravulizumab treatment (P10-11.001). Neurology. 2024;102(17_supplement_1). doi: 10.1212/WNL.0000000000205274.